Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...
Featuring a simply intelligence interface and substantial technological upgrades, the new multiplatform presents a new era in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback